This quarter's report includes full attribution analysis across all seven strategies, alongside detailed commentary from each portfolio manager on positioning and outlook.

Global Equities and Technology & Innovation were the strongest contributors to firm-wide performance over the period; the Health Sciences Fund lagged amid a broader repricing of clinical-stage biotechnology names.

Full holdings, performance tables and risk metrics are available in the downloadable report for registered investors.